Cargando…
Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma
Except for the traditional chemotherapy, few treatments strategy about miliary intrapulmonary carcinomatosis (MIPC) have been reported in the existing literature. In this report, we primarily discussed the possible etiology and the potentially effective treatment options for a patient with MIPC who...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293051/ https://www.ncbi.nlm.nih.gov/pubmed/35860549 http://dx.doi.org/10.3389/fonc.2022.922076 |
_version_ | 1784749525229895680 |
---|---|
author | Zhu, Jian Xu, Ya Huang, Wen-Cai Ji, Tao Ai, Guo-Ping Gao, Yan-Hong |
author_facet | Zhu, Jian Xu, Ya Huang, Wen-Cai Ji, Tao Ai, Guo-Ping Gao, Yan-Hong |
author_sort | Zhu, Jian |
collection | PubMed |
description | Except for the traditional chemotherapy, few treatments strategy about miliary intrapulmonary carcinomatosis (MIPC) have been reported in the existing literature. In this report, we primarily discussed the possible etiology and the potentially effective treatment options for a patient with MIPC who benefited from combined treatment. A nonsmoking woman was diagnosed with MIPC at an advanced stage. Gene detection showed an EGFR negative status. She accepted first-line chemotherapy with pemetrexed and cisplatin, and the tumor progressed. Next, PD-1 inhibitors plus pemetrexed and cisplatin were administered, and the tumor remained uncontrolled. After two cycles of recombinant human endostatin plus second-line chemotherapy, the numerous pulmonary nodules had all nearly completely disappeared, while an accentuated decrease in the primary tumor volume was observed. Moreover, biochemical markers, including the patient’s tumor markers, also trended toward normal. This report describes the first case of a MIPC patient who significantly responded to antiangiogenic therapy combined with chemotherapy. Anti-angiogenic therapy may be a possible strategy for the EGFR-negative lung adenocarcinoma population. |
format | Online Article Text |
id | pubmed-9293051 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92930512022-07-19 Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma Zhu, Jian Xu, Ya Huang, Wen-Cai Ji, Tao Ai, Guo-Ping Gao, Yan-Hong Front Oncol Oncology Except for the traditional chemotherapy, few treatments strategy about miliary intrapulmonary carcinomatosis (MIPC) have been reported in the existing literature. In this report, we primarily discussed the possible etiology and the potentially effective treatment options for a patient with MIPC who benefited from combined treatment. A nonsmoking woman was diagnosed with MIPC at an advanced stage. Gene detection showed an EGFR negative status. She accepted first-line chemotherapy with pemetrexed and cisplatin, and the tumor progressed. Next, PD-1 inhibitors plus pemetrexed and cisplatin were administered, and the tumor remained uncontrolled. After two cycles of recombinant human endostatin plus second-line chemotherapy, the numerous pulmonary nodules had all nearly completely disappeared, while an accentuated decrease in the primary tumor volume was observed. Moreover, biochemical markers, including the patient’s tumor markers, also trended toward normal. This report describes the first case of a MIPC patient who significantly responded to antiangiogenic therapy combined with chemotherapy. Anti-angiogenic therapy may be a possible strategy for the EGFR-negative lung adenocarcinoma population. Frontiers Media S.A. 2022-07-04 /pmc/articles/PMC9293051/ /pubmed/35860549 http://dx.doi.org/10.3389/fonc.2022.922076 Text en Copyright © 2022 Zhu, Xu, Huang, Ji, Ai and Gao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Zhu, Jian Xu, Ya Huang, Wen-Cai Ji, Tao Ai, Guo-Ping Gao, Yan-Hong Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma |
title | Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma |
title_full | Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma |
title_fullStr | Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma |
title_full_unstemmed | Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma |
title_short | Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma |
title_sort | case report: recombinant human endostatin plus chemotherapy for epidermal growth factor receptor-negative miliary lung adenocarcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293051/ https://www.ncbi.nlm.nih.gov/pubmed/35860549 http://dx.doi.org/10.3389/fonc.2022.922076 |
work_keys_str_mv | AT zhujian casereportrecombinanthumanendostatinpluschemotherapyforepidermalgrowthfactorreceptornegativemiliarylungadenocarcinoma AT xuya casereportrecombinanthumanendostatinpluschemotherapyforepidermalgrowthfactorreceptornegativemiliarylungadenocarcinoma AT huangwencai casereportrecombinanthumanendostatinpluschemotherapyforepidermalgrowthfactorreceptornegativemiliarylungadenocarcinoma AT jitao casereportrecombinanthumanendostatinpluschemotherapyforepidermalgrowthfactorreceptornegativemiliarylungadenocarcinoma AT aiguoping casereportrecombinanthumanendostatinpluschemotherapyforepidermalgrowthfactorreceptornegativemiliarylungadenocarcinoma AT gaoyanhong casereportrecombinanthumanendostatinpluschemotherapyforepidermalgrowthfactorreceptornegativemiliarylungadenocarcinoma |